| 1.208 -0.012 (-0.98%) 12-15 17:27 |
|
| Open: | 1.234 |
| High: | 1.242 |
| Low: | 1.186 |
| Pre. close: | 1.220 |
| Volume: | 169,040 |
| Avg. volume: | 279,242 |
| MA (50): | 1.220 |
| MA (200): | 1.298 |
| Year high: | 2.340 |
| Year low: | 0.863 |
| Market cap: | 80(M) |
| EPS: | -0.15 |
| PE ratio: | -8.05 |
| SELL | BUY |
| HeikinAshi: | |
| Kaufmans AMA: | |
| Chandelier (20): | |
| MA (5): | |
| MA (50): | |
| MACD (26,12,9): | |
| Slow KDJ (14,3): | |
| RSI (14): | |
| CCI (20): |
Mon, 15 Dec 2025
AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancers - The Manila Times
Thu, 11 Dec 2025
AB Science announces new publication on Medrxiv - GlobeNewswire
Wed, 03 Dec 2025
R/R Acute Myeloid Leukemia Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Foghorn Therapeutics, AB Science, Oncoceutics, Sanofi - Barchart.com
Wed, 22 Oct 2025
AB Science (EPA:AB shareholders incur further losses as stock declines 14% this week, taking five-year losses to 87% - simplywall.st
Fri, 17 Oct 2025
AB Science announces the successful completion of a EUR 2.8 million private placement - GlobeNewswire
Thu, 16 Oct 2025
AB Science provides intitial Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia - Yahoo Finance
©NovaStocks.com | euro Stocks quote, company news, stock charts, technical analysis. Data and information is provided for informational purposes only, is not intended for trading purposes and is not investment advice. Neither NovaStocks.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Market data provided by: Financial Modeling Prep
Privacy Policy: Third parties, including Google, may be placing and reading cookies on your browsers, or other methods to collect information as a result of ad serving on this website. Third parties' use of advertising cookies enables it and its partners to serve ads to you based on your visit to this site and/or other sites on the Internet. You may opt out of personalized advertising by visiting Ads Settings. If you choose to use this website, you agree to the collection and use of information in relation to this policy. The information collected is used for providing and improving the ads Service. We will not use or share information with anyone, and we do not store any data from users.